Cardiac troponin I (cTnI) and T (cTnT): Difference between revisions
Jump to navigation
Jump to search
m Bot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +) |
m Robot: Automated text replacement (-{{WikiDoc Cardiology Network Infobox}} +, -<references /> +{{reflist|2}}, -{{reflist}} +{{reflist|2}}) |
||
Line 1: | Line 1: | ||
{{SI}} | {{SI}} | ||
{{CMG}} | {{CMG}} | ||
Latest revision as of 15:20, 4 September 2012
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Cardiac troponin I (cTnI) and T (cTnT) are the current gold standards for detecting myocardial necrosis. Elevation in the setting of NSTE ACS is associated with a markedly increased risk of death and reinfarction. GP IIb/IIIa inhibitors can blunt the magnitude of this troponin release in NSTE ACS. Furthermore, troponin elevation identifies a subset of patients who enjoy the greatest benefit from both GP IIb/IIIa inhibition and early invasive therapy. [1] [2]